- 03-06-2026
- MEB
A pipeline meeting is a session where the MEB engages with a company to discuss new innovations and plans in the area of drug development for the upcoming period. The primary focus is on the general aspects of the company's product portfolio.
Next meeting: Wednesday, June 3, 2026.
Topic: Artificial intelligence in drug development
The use of artificial intelligence is transforming the world around us and has major advances for drug discovery and development. It is recognized that it will improve efficiency and timelines in drug development. Despite its potential, the implementation of artificial intelligence also faces challenges regarding data quality, algorithmic bias, interpretability and regulatory uncertainty.
This theme focusses on the use of artificial intelligence in drug development and clinical trials, and aims at discussing the following aspects:
• How to optimize and evaluate primary and secondary endpoints.
• The use in biomarker discovery.
• Impact on clinical trials, such as to increase precision, reduced trial sizes and patient selection.
• Potential for further development of the 3R’s principle.
• Challenges during development and impact on data quality and interpretability.
Applicants can apply for this pipeline meeting to present products in their pipeline related to this theme and elaborate on the challenges they face and how they wish to or have addressed them.
CCMO will participate during this pipeline meeting.
Applicants are informed that no scientific advice will be provided during pipeline meetings and the discussion will focus on new innovative developments and challenges in the portfolio of the applicant.
Registration deadline: Tuesday, April 7, 2026.
After the registration deadline, the MEB will select three companies from the submissions. The selected companies will be informed via email about their scheduled pipeline meeting. Companies that are not selected will receive a rejection notice via email. Notifications can be expected on Tuesday, April 14, 2026.
If a pharmaceutical company is selected to participate in a specific pipeline meeting, we ask the company to provide a briefing document to help the MEB participants prepare for the meeting. This briefing document should be submitted no later than Tuesday, May 12, 2026.